BioMarin Pharmaceutical Inc. (BMRN): Price and Financial Metrics


BioMarin Pharmaceutical Inc. (BMRN)

Today's Latest Price: $107.08 USD

0.43 (-0.40%)

Updated Jun 5 2:27pm

Add BMRN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

BMRN Stock Summary

  • BMRN has a higher market value than 90.68% of US stocks; more precisely, its current market capitalization is $19,441,770,389.
  • With a price/earnings ratio of 170.53, Biomarin Pharmaceutical Inc P/E ratio is greater than that of about 97.18% of stocks in our set with positive earnings.
  • Price to trailing twelve month operating cash flow for BMRN is currently 221.09, higher than 98.86% of US stocks with positive operating cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biomarin Pharmaceutical Inc are DXCM, SNPS, ANET, CDNS, and GDDY.
  • BMRN's SEC filings can be seen here. And to visit Biomarin Pharmaceutical Inc's official web site, go to www.biomarin.com.
BMRN Daily Price Range
BMRN 52-Week Price Range

BMRN Stock Price Chart More Charts


BMRN Price/Volume Stats

Current price $107.08 52-week high $112.57
Prev. close $107.51 52-week low $62.88
Day low $105.79 Volume 678,396
Day high $109.71 Avg. volume 1,598,570
50-day MA $92.84 Dividend yield N/A
200-day MA $82.74 Market Cap 19.36B

BioMarin Pharmaceutical Inc. (BMRN) Company Bio


BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company was founded in 1996 and is based in San Rafael, California.


BMRN Latest News Stream


Event/TimeNews Detail
Loading, please wait...

BMRN Latest Social Stream


Loading social stream, please wait...

View Full BMRN Social Stream

Latest BMRN News From Around the Web

Below are the latest news stories about Biomarin Pharmaceutical Inc that investors may wish to consider to help them evaluate BMRN as an investment opportunity.

The Daily Biotech Pulse: Adamas Rallies On FDA Acceptance, Oxford Immunotech Reportedly Gets $400M Bid

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 4) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Passage Bio Inc (NASDAQ: PASG ) Qiagen NV (NYSE: QGEN ) Replimune Group Inc (NASDAQ: REPL ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 4) Evofem Biosciences Inc (NASDAQ: EVFM )(priced its 28.5 million common stock offering) Iterum Therapeutics PLC (NASDAQ: ITRM ) Stocks In F...

Benzinga | June 5, 2020

The Daily Biotech Pulse: Positive Readout For Kezar, AstraZeneca Stitches Oncology Partnership, D-Day For Merck's Triple Combo Antibiotic

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week Highs June 3) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Black Diamond Therapeutics Inc (NASDAQ: BDTX ) Fortress Biotech (NASDAQ: FBIO ) Imara Inc (NASDAQ: IMRA ) Inari Medical Inc (NASDAQ: NARI ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Kala Pharmaceuticals Inc (NASDAQ: KALA ) Keros Therapeutics Inc (NASDAQ: KROS ) ORIC Pharmaceuticals Inc (NASDAQ: ORIC ) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Pliant Therapeutics Inc (NASDAQ: PLRX ) (went public Wednesday) Protara Therapeutics Inc (NASDAQ: TARA ) Qiagen NV (NYSE: QGEN ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) United Therapeutics Corporation (NASDAQ:...

Benzinga | June 4, 2020

BioMarin to Participate in Two Upcoming Virtual Investor Conferences

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer; Henry Fuchs, M.D., President, Worldwide Research & Development; and Brian Mueller, Acting Chief Financial Officer, will participate in the Jefferies Virtual Healthcare Conference on June 4, 2020 at 4:00pm ET and the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020 at 2:10pm ET. An audio webcast of the presentation will be available live. You can access the webcast at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference.

Yahoo | June 3, 2020

BioMarin Provides Positive Gene Therapy Update For Severe Hemophilia A

Global biotech BioMarin Pharmaceutical Inc. (BMRN) has announced updated results of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy … The post BioMarin Provides Positive Gene Therapy Update For Severe Hemophilia A appeared first on Smarter Analyst .

Smarter Analyst | June 1, 2020

2 Best Biotech Stocks to Buy Right Now

Revenue is climbing at these biotech companies. And one of them is waiting for what could be an historic product approval.

Yahoo | June 1, 2020

Read More 'BMRN' Stories Here

BMRN Price Returns

1-mo 12.72%
3-mo 13.59%
6-mo 33.98%
1-year 33.04%
3-year 19.51%
5-year -13.54%
YTD 26.65%
2019 -0.70%
2018 -4.51%
2017 7.64%
2016 -20.92%
2015 15.88%

Continue Researching BMRN

Here are a few links from around the web to help you further your research on Biomarin Pharmaceutical Inc's stock as an investment opportunity:

Biomarin Pharmaceutical Inc (BMRN) Stock Price | Nasdaq
Biomarin Pharmaceutical Inc (BMRN) Stock Quote, History and News - Yahoo Finance
Biomarin Pharmaceutical Inc (BMRN) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0437 seconds.